Research Studies and Clinical Trials Search
Results
Diabetes Type I: A study about teplizumab, an investigational drug, and its ability to protect cells producing insulin.
This study is being done for kids, adolescents, and young adults: * Ages: 1- 17 years * Recent diagnosis of Diabetes Type I (T1D)...
This study is being done for kids, adolescents, and young adults: * Ages: 1- 17 years * Recent diagnosis of Diabetes Type I (T1D). The main goal of the study is to see if teplizumab can work better than a placebo (a look-alike with no medicine in it) in helping people keep their blood sugar in a healthy range or use less mealtime insulin. Children's Mercy is one of many sites participating in this study.
Diabetes Type I: A study of medication, CNP-103, to prevent islet cell destruction.
This study is being done for adolescents/young adults/adults: * 12-35 years old. * Newly diagnosed Type I Diabetes...
This study is being done for adolescents/young adults/adults: * 12-35 years old. * Newly diagnosed Type I Diabetes. This study is looking to see if the medication, CNP-103, can help the body preserve its ability to produce insulin by reducing the attack on the insulin-producing beta cells in the pancreas.
Prediabetes/Diabetes, Polycystic Ovary Syndrome (PCOS), Rapid Weight Gain, and/or Insulin Resistance: A study of metformin in youth ages 7 to 21 years old
This study is for children's who are: • Ages 7 to 21 years old • Currently taking Metformin twice a day (not XR) This is a study about Prediabetes/Diabetes, Polycystic Ovary Syndrome (PCOS), Rapid Weight Gain, and/or Insulin...
This study is for children's who are: • Ages 7 to 21 years old • Currently taking Metformin twice a day (not XR) This is a study about Prediabetes/Diabetes, Polycystic Ovary Syndrome (PCOS), Rapid Weight Gain, and/or Insulin Resistance diagnosis. Researchers at Children's Mercy want to learn more about Metformin. The purpose of this study is to learn how Metformin is processed in the body and to discover how to best dose Metformin in children.
SAFEGUARD: A study to see if the new study drug called SAB-142 is safe and helps people who have T1D.
This study is being done for patients: • Age: 12 years and older • Recent Diabetes type 1 diagnosis (within the last 100 days)...
This study is being done for patients: • Age: 12 years and older • Recent Diabetes type 1 diagnosis (within the last 100 days) People with Type 1 Diabetes (T1D) do not have enough insulin. Insulin controls a type of sugar called glucose in the body. If the body has too much glucose, it can cause damage to it. The purpose of this study is to determine whether the new study drug, SAB-142, is safe and helps people with T1D. SAB-142 is not insulin and it will be given in addition to insulin treatments already prescribed.
Type I Diabetes: A study to better understand those at risk for developing Type I Diabetes
The overall objective of this study is to perform baseline and repeat assessments over time of the metabolic and immunologic status of individuals at risk for type 1 diabetes (T1D) to: (a) characterize their risk for developing T1D and identify subjects eligible for prevention...
The overall objective of this study is to perform baseline and repeat assessments over time of the metabolic and immunologic status of individuals at risk for type 1 diabetes (T1D) to: (a) characterize their risk for developing T1D and identify subjects eligible for prevention trials, (b) describe the pathogenic evolution of T1D, and (c) increase the understanding of the pathogenic factors involved in the development of T1D.
Youth with Insulin Treated Diabetes: A study to collect feedback on a diabetes phone app
This study is for: - Participants include Parent(s)/Guardians of children age 1-18 who have insulin treated diabetes or youth age 13-22 who have insulin treated diabetes The goal of this study is to test if a diabetes phone app has an impact on engagement and understanding of...
This study is for: - Participants include Parent(s)/Guardians of children age 1-18 who have insulin treated diabetes or youth age 13-22 who have insulin treated diabetes The goal of this study is to test if a diabetes phone app has an impact on engagement and understanding of diabetes care.